Tajikistan Medical Device Regulation 2026: Ministry of Health versus the State Supervisory Body for Pharmaceutical Activity

1. Key takeaways

Medical device regulation in Tajikistan is divided between two authorities: the Ministry of Health makes the rules, while the State Supervisory Body for Pharmaceutical Activity handles registration, review and supervision. Article 8 of Law No. 1893 lists 22 powers of the Ministry of Health, and Article 9 lists 10 powers of the supervisory body; among them, item 8 of Article 9 expressly assigns the registration and re-registration of medicines, medical goods, parapharmaceuticals and designated products to the supervisory body. GRZAN adheres to one working principle throughout submissions and communications: watch the Ministry of Health for procedural changes, and approach the supervisory body for the progress of individual cases.

2. Legal basis

3. Expert insights

Insight 1: This is a structure that separates rule-making from case execution, and the most common confusion concerns which authority to address. Article 8 places the power to develop numerous procedural documents with the Ministry of Health — the registration and re-registration procedures, change procedures, conformity assessment procedures, clinical trial procedures, unified requirements for labeling and packaging, the main medicines list, and destruction procedures are all developed and approved by the Ministry of Health. Article 9 places executive power with the supervisory body — registration, re-registration, expert review, license issuance, supervisory inspections, and pharmacovigilance. The experience of GRZAN is: when a client asks whether a requirement will change, track the normative documents of the Ministry of Health; when a client asks where their case is stuck, engage the supervisory body.

Insight 2: The fee competence in Article 9(4) is the basis for verifying whether a quotation is genuine. The supervisory body, together with the authorized state body in the antitrust sphere, approves the fee standards for quality certification and expert assessment services. This means that conformity assessment and expert assessment services have a statutory fee basis. When reviewing third-party quotations, GRZAN requires the counterparty to produce the document setting out the fee basis rather than accepting verbal quotations — because Article 9(4) locks pricing authority to joint approval by the two authorities.

Insight 3: Item 17 of Article 8 is a window that is easily overlooked. That provision empowers the Ministry of Health, where necessary, to recognize the pharmacopoeias and quality standards for medicines and medical goods of other states. The implication for Chinese manufacturers is that when Chinese national standards or international standards create an interface problem with Tajik quality determination requirements, a recognition pathway led by the Ministry of Health exists and can be raised as a technical argument during registration communication — but it is not automatically applicable and must be pursued case by case.

Insight 4: Article 6 also lists the government as a state regulation actor, and Article 7 separately provides for government powers. Where import and export procedures (Article 26(5)), price control procedures (Article 28), and the categories and conditions of preferential supply (Article 22(4)) are involved, the rule-making power rests with the government rather than the Ministry of Health, so the tracking level must be raised one tier further.

4. Practical recommendations

1. Establish a dual-channel tracking mechanism for the two authorities. The Ministry of Health channel mainly tracks the development and revision of normative documents; the supervisory body channel mainly tracks case progress and inspection activity. Information on the two lines updates at different frequencies and should not be merged into one process.
2. Request the currently valid version of procedural documents before submission. Article 17(12) assigns the power to develop registration, re-registration and change procedures for medical goods to the Ministry of Health, and these documents may already have been updated. The practice of GRZAN is to re-request them at the start of every project rather than reuse the version from a previous project.
3. Obtain formal fee documentation. For fees involving conformity assessment, quality certification and expert assessment services, invoke Article 9(4) to require the supervisory body or its subordinate institutions to issue the fee basis document, and compare it item by item against the internal budget.
4. Prepare technical materials for a recognition application where standards interface issues arise. If Article 8(17) is to be invoked, prepare a separate standards comparison document alongside the registration dossier, demonstrating the equivalence of the cited standards with Tajik requirements.

5. Verification checklist

• □ Distinguished the boundary of powers between the Ministry of Health (Article 8) and the supervisory body (Article 9)
• □ Confirmed that registration and re-registration are performed by the supervisory body (Article 9, item 8)
• □ Obtained the currently valid version of the registration procedure documents (competence assigned to the Ministry of Health under Article 17(12))
• □ Obtained formal fee documentation for conformity assessment and expert assessment services (Article 9(4))
• □ Established a dual-channel regulatory tracking mechanism for the two authorities
• □ Confirmed that rule-making power rests with the government for import and export, pricing and preferential supply matters (Articles 7, 26 and 28)
• □ Assessed whether to invoke the Article 8(17) pathway for recognition of foreign pharmacopoeias and standards

Regulatory information verified as of October 29, 2026.

In the Central Asian market, the core capabilities of GRZAN concentrate on three points: first, distinguishing the different legal status of each market within the Eurasian Economic Union — Kazakhstan and Kyrgyzstan are full member states offering a dual choice between the national track and the union track; Uzbekistan is an observer state with only the national track; Tajikistan and Turkmenistan are outside the union framework and must follow purely national procedures. Second, local authorized representative services, acting as the statutory representative of manufacturers in these countries and undertaking registration submission, regulatory communication and post-market reporting obligations. Third, quality system and testing support, assisting in establishing a quality management system that meets ISO 13485 requirements and connecting with locally accredited laboratory resources.

Business inquiries: info@grzanglobal.com